Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs

Published by: Business Insights

Published: Dec. 1, 2007 - 195 Pages

Table of Contents

Lifestyle Drugs

Executive Summary

Introduction

Alcohol Dependence

Alopecia

Obesity

Oral Contraception

Sexual Dysfunction

Skin Aging

Smoking Cessation

Chapter 1 Introduction

Summary

Introduction

Defining the Market

Defining Lifestyle Conditions

Social Characteristics

Disease characteristics

Product Characteristics

Sales Potential

High demand upon launch

Ability to create new markets

Drivers of demand for lifestyle drugs

An aging population

Growth in disposable income

Increasing consumer awareness

Rise in branding activities

Barriers to market growth

Demonstrating favorable health economics to payors - the road to rationing

Drug abuse and misuse

Loss of corporate control over brand

Reimbursement

Recommendations for securing reimbursement of lifestyle drugs

Data Caveats

Chapter 2 Alcohol Dependence

Summary

Overview of Alcohol Dependence

Diagnosis

Measuring & Diagnosing

Pathophysiology

Factors Influencing Severity of Symptoms

Gender Influence

Genetic Influence

Prevalence

Reimbursement

Drug Therapy

Disulfiram (Aldehyde Dehydrogenase Inhibitor)

Naltrexone

Benzodiazepines

Sodium Oxybate

Acamprosate

Metadoxine

Market Analysis

Campral (Acamprosate)

Antabuse

Naltrexone Therapies

Pipeline Outlook

Chapter 3 Alopecia

Summary

Overview of Alopecia

Pathophysiology & Etiology

Alopecia areata

Androgenetic alopecia

Anagen effluvium

Telogen effluvium

Scarring alopecia

Self-induced alopecia

Other causes

Prevalence

Drug Therapy

Market Analysis

Propecia

Rogaine (minoxidil)

Pipeline Outlook

Chapter 4 Obesity

Summary

Overview of Obesity

Definition

Measuring & Diagnosing Obesity

Pathophysiology & etiology

Factors influencing severity of Obesity

Age and Gender Influence

Genetic Influence

Nutritional Influence

Prevalence

Reimbursement

Drug Therapy

Market Analysis

Xenical

Reductil/Meridia/Ectiva (sibutramine)

Acomplia (Rimobant)

Company Analysis

Pipeline Outlook

Novel Mechanisms

Chapter 5 Oral Contraception

Summary

Overview of Oral Contraception

The female reproductive population

Drug therapy

Side Effect Profile

Market Analysis

The Yasmin Franchise

Ortho Tri-cyclen Lo

Estrostep Fe

Ortho Evra

Mirena

Seasonale

Reimbursement

Promotional Spend

Company Analysis

Pipeline Outlook

Chapter 6 Sexual Dysfunction

Summary

Overview of Sexual Dysfunction

Male Sexual Dysfunction

Diagnosis

Pathophysiology & diagnostic indicators

Erectile dysfunction (ED)

Loss of libido

Priapism

Peyronie’s disease

Premature and delayed ejaculation

Contributing Factors

Prevalence

Reimbursement

Drug Therapy

PDE-5 Inhibitors

Alprostadil

Market Analysis

Viagra

Cialis

Levitra

Promotional Spend

Product Pipeline

Delivery Mechanism

Niche Markets

OTC Retail

Phosphodiesterase Inhibitors

Female sexual Dysfunction

Diagnosis

Sexual desire disorders

Female sexual arousal disorder

Sexual orgasmic disorder

Sexual pain disorders

Measuring & diagnosing

Factors influencing the severity of female sexual dysfunction

Genetic Influence

Prevalence

Drug Therapy

Pipeline outlook

Chapter 7 Skin Aging

Summary

Overview of Skin Aging

Pathophysiology and etiology

Factors Driving Demand

Demographic Influence

Personal Appearance Gain

Acceptance of Cosmetic Procedures

Prevalence

Drug Therapy

Market Analysis

Renova (tretinoin)

Retin-A/Retin-A Micro (tretinoin)

Botox (botulinum toxin type A)

Tazarotene

Company Activities

Product Pipeline

Chapter 8 Smoking cessation

Summary

Overview of smoking cessation

Measuring & Diagnosing

Pathophysiology & etiology

Factors influencing smoking cessation

Prevalence

Policy & Reimbursement

Drug Therapy

Nicotine replacement therapy

Antidepressants

Nicotine partial receptor agonists

Market Analysis

Champix/Chantix (US)

Nicotine Replacement Therapies

Zyban

Promotional Spend

Company Analysis

Pipeline Outlook

Opioid Receptor Agonists

Cannabinoid Receptor Antagonists

Clonidine

Nicotine Conjugate Vaccine

Glycine Receptor Antagonist

Chapter 9 Appendix

IMS data

Alcohol Dependence

Alopecia

Obesity

Oral Contraception

Sexual Dysfunction

Smoking Cessation

Pearl Index

Index

List of Figures

Figure 1.1: Defining Lifestyle Drugs

Figure 1.2: The reimbursement decision process

Figure 1.3: Improving reimbursement status of lifestyle drugs: a three-pronged approach

Figure 2.4: Geographic market shares for Alcohol Dependence Drugs by sales revenue, 2006 ($m)

Figure 2.5: Pipeline for alcohol dependence therapies, 2007

Figure 3.6: Pipeline for alopecia therapies, 2007

Figure 4.7: Geographic market shares for anti-obesity products by sales revenue, 2006 ($m)

Figure 4.8: Pipeline for obesity therapies, 2007

Figure 5.9: Revenues by drug class for prescription oral contraceptives ($m), 2006; EU5, Japan, USA

Figure 5.10: Geographic market sizes for prescription oral contraceptives by sales revenue, 2006 ($m)

Figure 5.11: Promotional spend on top oral contraceptive brands in major markets (EU5, USA), 2006 ($m)

Figure 5.12: Pipeline for oral contraceptives, 2007

Figure 6.13: Geographic market size for erectile dysfunction products by sales revenue, 2006, $m

Figure 6.14: Pipeline for erectile dysfunction therapies, 2007

Figure 6.15: Possible caused of female sexual dysfunction

Figure 6.16: Pipeline for female sexual dysfunction therapies, 2007

Figure 7.17: Factors influencing cosmeceutical consumption across the major markets

Figure 7.18: Demographics of skin aging concerns

Figure 7.19: Pipeline for skin aging therapies, 2007

Figure 8.20: Global sales of smoking cessation drugs, 2006 ($m)

Figure 8.21: Pipeline for smoking cessation products, 2007

List of Tables

Table 1.1: Distribution channels covered in IMS MIDAS database

Table 2.2: Top 10 Alcohol dependency therapies 2007, Growth Metrics

Table 2.3: Pipeline analysis; alcohol dependence therapies

Table 3.4: Drug therapy for common types of alopecia

Table 3.5: Top 10 alopecia brands 2007, growth metrics

Table 4.6: Classification of overweight, obesity by BMI, waist circumference and associated disease risk

Table 4.7: Obesity-linked Genotypes

Table 4.8: Projected prevalence of obesity, 2006-2012 (‘000s)

Table 4.9: Top 10 anti-obesity brands 2007, growth metrics

Table 4.10: Obesity pipeline products

Table 5.11: Forecast growth of the childbearing population; EU5, US and Japan, 2007-10 (000s)

Table 5.12: Top 10 oral contraceptive brands, 2007 ($m)

Table 6.13: Common physiological causes of erectile dysfunction

Table 6.14: Prevalence of moderate and severe ED in the seven major markets

Table 6.15: Top 5 erectile dysfunction brands 2007; growth metrics

Table 6.16: Pipeline analysis; female sexual dysfunction (FSD)

Table 7.17: Symptoms of skin aging

Table 8.18: Factors influencing smoking cessation success

Table 8.19: Smoking prevalence; EU5, US, Japan; 2002

Table 8.20: Top 10 smoking cessation brands 2007, growth metrics

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.